November 25, 2019

CymaBay Therapeutics Stops Clinical Development of Seladelpar

The company announced it is terminating a Phase 2b study, a Phase 2 study and putting on hold seladelpar in...
November 4, 2019

CymaBay Therapeutics Reaches Target Enrollment in ENHANCE Phase 3 Study

The study is evaluating its seladelpar in patients with primary biliary cholangitis with enrollment to be completed by end of...
June 18, 2019

CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar

CymaBay Therapeutics (NASDAQ:CBAY) has announced that the US Food and Drug Administration (FDA) has cleared the company’s investigational new drug...